Arteriocyte Medical Systems has received U.S. Food and Drug Administration approval for a product associated with its Magellan stem cell harvesting medical device. The latest FDA approval for the Cleveland-based company concerns an anticoagulant solution used in the device, which harvests and quickly concentrates stem cells and blood platelets during surgeries. These concentrated cells can […]
Stem cell company Arteriocyte has received U.S. Food and Drug Administration approval to begin a phase 1 clinical trial that will treat soldiers at risk for compartment syndrome. Compartment syndrome is a serious condition that involves a buildup of fluid pressure in soft tissue compartments within the body. It’s caused by trauma and can lead […]
Stem cell developer Arteriocyte has signed a research and development deal with the Army to investigate new therapies for orthopedic trauma and battlefield injuries. Arteriocyte is already working with the U.S. Army Institute of Surgical Research (USAISR) to develop stem cell-based, point-of-care therapies for amputation prevention, burn debridement and post-surgical wound infection prevention, according to […]
Stem cell developer Arteriocyte has received approval from the U.S. Food and Drug Administration to begin a clinical trial for the treatment of critical limb ischemia.
Arteriocyte Inc. has launched a stem cell-based product that allows researchers to grow red blood cells outside the human body.
Don Brown, CEO of Cleveland-based stem cell company Arteriocyte, discusses his company's progress towards getting its therapies on the market and its priorities going forward.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
US Endoscopy, the endoscopy device design and manufacturing company in Mentor, has released the Entrada colonic overtube, which offers more control during colonoscopy in patients with tortuous sigmoid looping.
Case Western Reserve University has spent most of the last nine years building its Science, Technology & Entreprenuership Program program on that philosophy, trying to turn a perceived weakness into a strength. It can't lure business-minded scientists into the program with promises of working at big-name medical companies comparable to what's in Southern California or in the East Coast's pharmaceutical region. Instead, it offers the offer unglamorous, do-it-all experience of working in small startups, exposed to all aspects of a business.
Altogether, there are easily $50 million in health-related federal earmarks from Ohio legislators that could fund projects from the James Cancer Hospital at Ohio State University to a Youngstown company whose device is ideal for victims of battlefield trauma. Votes in Senate and House committees are expected this month to determine whether the institutions would get some, all or any of their requests.
Medical device company Arteriocyte Medical Systems has invested an undisclosed amount of money in a Park City, Utah, company that developed a disposable device to extract fluids, tissues and blood clots from patients. Bone marrow extracted by the device could be used by Arteriocyte Medical's Magellan devices, which harvest and quickly concentrate stem cells and blood platelets during surgeries.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A $10 million public-private deal with Cardinal Health and Ohio State was the largest of several Third Frontier grants for biomedical companies or organizations announced Wednesday. Altogether, imaging companies and organizations received $20 million in funding. Out of eight total grant announcement, Cleveland-area companies were involved in five.
CLEVELAND, Ohio — Stem-cell companies may be able to blunt the economic doldrums of 2009 with new opportunities courtesy of a new administration, according to the interim chief executive of Cleveland’s Cell Targeting Inc. Cell Targeting on Thursday said it appointed Joseph Wagner as its chief technology officer. Wagner for the last seven years worked […]
